XPro1595 Patient Experience скачать в хорошем качестве

XPro1595 Patient Experience

This 63 year old male with Early Alzheimer’s Disease who participated in the open label Phase I trial in Alzheimer’s disease with biomarkers of inflammation. The patient was part of the of the 1mg/kg/week dose cohort. The patient chose to enroll in the open label extension after he completed the 3 month Phase I trial. After completion of the 12-month open label extension, his physician requested the patient remain on study drug using the Australian Special Access Scheme. The video was made after more than six months of treatment with the study drug. The patient remains on weekly therapy more than 3 years after beginning the Phase I trial. This video has been made public with the permission of the patient. • This is the story of one participant from a Phase 1 trial of XPRO1595 for the treatment of AD. • XPRO1595 is for investigational use only and has not been found to be safe or effective by any health authority. • Further clinical studies of XPRO1595 are needed. No conclusions about the safety or efficacy of XPRO1595 for any use can be drawn. • This video is intended for the financial community interested in learning more about INmune Bio and its research.